Analyst reactions and Q1 surprise

PROCEPT BioRobotics (PRCT) drew fresh attention after reporting better than expected fiscal Q1 results, which prompted several research updates and a double digit after hours move in the stock.

Piper Sandler highlighted strong domestic capital placements and record average selling prices as key supports for its updated view. Baird refreshed its models on the earnings surprise but kept a more cautious stance on long term adoption.

Despite the post earnings jump, the stock’s recent pattern has been mixed, with a 12.68% 1 month share price return and a year to date share price decline of 10.76%. The 1 year total shareholder return is down 53.10% and the 3 year total shareholder return is down 12.58%, suggesting longer term momentum has been weak even as shorter term sentiment has improved.

If this kind of sharp move has your attention, it may be a good moment to widen your watchlist and check out 34 robotics and automation stocks

So with PROCEPT BioRobotics trading at $27.45 and sitting about 11% below an average analyst price target of $30.44, is there a potential mispriced opportunity here, or has the market already incorporated the growth story into the current share price?

Most Popular Narrative: 10% Undervalued

With PROCEPT BioRobotics last closing at $27.45 against a narrative fair value of $30.44, the valuation story hinges on how fast Aquablation adoption can build over time.

The ongoing expansion of HYDROS robotic system placements into both high-volume and mid/lower volume hospitals, in conjunction with rising utilization by a growing base of engaged surgeons, indicates significant untapped market potential, driving recurring consumables revenue growth and eventual expansion in gross and operating margins.

Curious what kind of revenue trajectory and margin shift would need to materialize to support that fair value, and how long the model assumes losses continue before earnings turn a corner? The narrative lays out a detailed path that links procedure volumes, pricing and share count to a future earnings base and a premium P/E multiple, all discounted back at a 7.9% rate.

Result: Fair Value of $30.44 (UNDERVALUED)

However, this depends on PROCEPT growing Aquablation use as planned and managing execution shifts in sales coverage, discounting and supply chain without prolonging operating losses.

Another View on PROCEPT BioRobotics' Valuation

The analyst narrative leans on earnings in 2029 and a future P/E of 29.6x to argue PRCT looks about 10% undervalued at $27.45 versus a $30.44 fair value. Yet today the stock trades on a P/S of 4.9x, richer than the US Medical Equipment industry at 2.8x and above a fair ratio of 3.3x. This points to valuation risk if sentiment cools.

If earnings are still years away and the current P/S is already above where the fair ratio suggests the market could settle, how much of the Aquablation story do you think is already reflected in the price, and how much upside are you really being paid for?

Next Steps

Seen enough to sense both enthusiasm and concern around PROCEPT BioRobotics? Take a moment to review the data yourself, pressure test the assumptions, and weigh the 1 key reward and 2 important warning signs.

Looking for more investment ideas?

If PROCEPT BioRobotics has sharpened your focus, do not stop here; there are plenty of other stocks that could better match your goals and risk comfort.

• Target dependable growth prospects by checking companies on the 46 high quality undervalued stocks that combine quality fundamentals with prices that may not fully reflect their strengths.
• Prioritize resilience and sleep better at night by reviewing stocks in the 65 resilient stocks with low risk scores that score well on financial strength and volatility.
• Hunt for tomorrow's quiet standouts by scanning the screener containing 22 high quality undiscovered gems before other investors start paying closer attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.